In this episode, we feature Plenary Lecture 04 from the AD/PD™ 2025 International Conference — the Eric N. Birch Memorial Lecture, titled “Treatment of DLB and PDD: Status and New Developments.”
Chaired by Dr. Sandra Moose (USA) and presented by Prof. Dag Aarsland (UK), this important plenary cast a spotlight on two often-overlooked conditions in the neurodegenerative disease landscape: Dementia with Lewy Bodies (DLB) and Parkinson’s Disease Dementia (PDD).
Prof. Aarsland delivered a comprehensive update on the therapeutic landscape of Lewy body dementia, both current standards and promising directions in the pipeline.
Key highlights include:
• The persistent underdiagnosis and underfunding of Lewy body dementia research, despite its high prevalence
• An overview of current evidence-based treatments, including cholinesterase inhibitors and Pimavanserin for psychosis
• A review of ongoing and recent drug trials — including Neflamapimod, CT1812, Ambroxol, and Dantrolene
• The importance of repurposed drugs and symptom management toolkits like the Diamond Lewy Toolkit
• The emerging role of non-pharmacological approaches such as cortical stimulation
• New directions in biomarker-based stratification for targeted therapies
• A call for better trial designs and increased research collaboration in the DLB/PDD space
This episode is especially relevant for neurologists, clinical researchers, drug developers, healthcare policymakers, and advocacy groups working to improve outcomes for people living with Lewy body and Parkinson’s-related dementias.
This podcast was created using AI to provide a quick and insightful summary of an AD/PD™ 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.
The AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, took place on April 1-5, 2025, in Vienna Austria.
https://adpd.kenes.com/
In this episode, we spotlight Forum Discussion 03 from the AD/PD™ 2025 International Conference: “Improving the Therapeutic Potential of Immunotherapies in AD – Can Novel Strategies or Next Generation Drugs Halt or Further Delay Disease Progression?”
Chaired by Dr. Rudolph Tanzi (USA) and Dr. Suzanne Hendrix (USA), this thought-provoking panel brought together leaders in Alzheimer’s disease research and development: Dr. Chad Swanson, Dr. Donna Wilcock, Dr. Yuval Zabar, Dr. Janice Smith, and Dr. Eric Siemers.
The discussion centered on how the next generation of Alzheimer’s immunotherapies can go beyond current anti-amyloid treatments. With an eye on efficacy, safety, accessibility, and clinical outcomes, the panel explored what’s needed to truly move the field forward.
Key highlights include:
• The limitations of current anti-amyloid therapies and how to maximize their real-world impact• Infrastructure and access issues — from infusion centers to specialist shortages
• Potential of next-gen strategies, including combination therapies and novel mechanisms
• The role of blood-based biomarkers and real-world data in refining treatment selection
• Challenges and promise of active vaccination for long-term AD prevention
• Cost-effectiveness and the need to measure outcomes that truly matter to patients
This episode is relevant for clinical researchers, neurologists, biotech developers, regulatory experts, and anyone invested in the future of disease-modifying treatments for Alzheimer’s.
This podcast was created using AI to provide a quick and insightful summary of an AD/PD™ 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.
The AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, took place on April 1-5, 2025, in Vienna Austria.
https://adpd.kenes.com/
In this episode, we explore Plenary Lecture 2 from the AD/PD™ 2025 International Conference: “GLP-1R Agonist Effects in Brain.”
Moderated by Dr. Cynthia Lemere (USA) and Dr. Henrietta Nielsen (Sweden), this featured lecture was presented by Dr. Lotte Bjerre Knudsen (Denmark), Chief Scientific Advisor at Novo Nordisk. A pioneering force in GLP-1 drug development and co-inventor of liraglutide, Dr. Knudsen shared novel data on semaglutide’s potential neuroprotective mechanisms, as the drug advances through Phase 3 trials (EVOKE & EVOKE+) for Alzheimer’s disease.
Key highlights include:
• GLP-1’s dual role as a hormone and neurotransmitter with CNS effects
• Evidence that semaglutide dampens hippocampal inflammation and supports microglial homeostasis
• Insights into how GLP-1R agonists may stabilize plaques and modulate APOE-related pathways
• Potential applications for GLP-1 drugs beyond metabolic disorders, including AD and neurodegeneration
• How cardiovascular and anti-inflammatory benefits seen in obesity and diabetes may translate to brain health
This episode is especially relevant for neurologists, neuroscientists, translational researchers, pharmaceutical professionals, and anyone interested in repurposing metabolic therapies for neurodegenerative diseases.
This podcast was created using AI to provide a quick and insightful summary of an AD/PD™ 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.
The AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, took place on April 1-5, 2025, in Vienna Austria.
https://adpd.kenes.com/
In this episode, we dive into one of the most forward-looking conversations from the AD/PD™ 2025 International Conference — Forum Discussion 2, "Integrating Blood-Based, CSF and Imaging Biomarkers With Digital Tools and AI in MCI & AD."
Moderated by Dr. Oskar Hansson (Sweden) and Dr. Melissa Murray (USA), this dynamic session was led by Dr. Rhoda Au (USA), Prof. Charlotte Teunissen (Netherlands), Dr. Danielle Graham (USA), Dr. Bryan Cobb (USA) and Dr. Tobias Bittner (Switzerland). The discussion explored how emerging biomarkers — from blood-based diagnostics to digital tools powered by AI — are reshaping how we detect and monitor Alzheimer’s disease. But how close are we to true clinical validation?
Key highlights include:
• The promise of IVD-cleared blood-based tests for amyloid positivity by 2025
• Global progress and regulatory differences in the US and Europe
• The critical role of clinical guidelines, education, and confirmatory testing
• How digital biomarkers may detect cognitive decline earlier than ever
• Four intended uses of digital tools in clinical and research settings
• Challenges in validating digital measures with the same rigor as biological ones
This episode is relevant for clinicians, researchers, biotech professionals, regulators, and digital health innovators working on early detection and precision medicine in Alzheimer’s disease.
This podcast was created using AI to provide a quick and insightful summary of an AD/PD™ 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.
The AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, took place on April 1-5, 2025, in Vienna Austria.
https://adpd.kenes.com/
In this episode of AD/PD™ Session Spotlight, we present Plenary Lecture 1 from AD/PD™ 2025, titled "The Alzheimer's Disease Drug Development Pipeline: Observations and Implications," delivered by Dr. Jeffrey Cummings (USA) and chaired by Dr. Cynthia Lemere (USA) and Dr. Henrietta Nielsen (Sweden).
Renowned for his leadership in Alzheimer’s research, Dr. Cummings offers a sweeping and data-driven overview of the evolving landscape of Alzheimer’s drug development—spotlighting trends, challenges, and opportunities shaping the future of treatment.
Key highlights include:
• A record 182 active trials involving 138 unique drug candidates, reflecting unprecedented momentum in the pipeline
• The rising importance of biomarkers across all trial phases, from early discovery to outcome measurement
• A growing focus on inflammation and immunity as therapeutic targets
• Insights into global trial dynamics, including site participation, recruitment hurdles, and regional disparities
• The role of repurposed drugs and innovative trial designs in accelerating progress
• A look ahead at anticipated readouts from ongoing trials, and what they may mean for patients and providers
This episode is highly relevant for drug developers, clinical trial professionals, regulatory stakeholders, and anyone invested in the future of Alzheimer's treatment, offering a clear-eyed perspective on where the field is headed—and why it matters.
This podcast was created using AI to provide a quick and insightful summary of an AD/PD™ 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.
The AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, took place on April 1-5, 2025, in Vienna Austria.
https://adpd.kenes.com/
In episode 2 of AD/PD™ Session Spotlight, we feature Plenary Lecture 3, the Don Price Memorial Lecture, titled "Plasma Biomarkers for Dementias in the Era of Disease-Modifying Therapies," presented by Prof. Charlotte Teunissen (The Netherlands) and chaired by Dr. Sangram Sisodia (USA).
This compelling lecture honors the legacy of Dr. Donald L. Price and explores the transformative role of plasma biomarkers in Alzheimer’s disease care, from diagnosis to personalized treatment strategies.
Key highlights include:
• The clinical readiness of plasma biomarkers like P-tau217 for diagnosing and monitoring Alzheimer’s disease
• Insights from ongoing implementation studies in the Netherlands and international efforts to standardize biomarker use
• The role of biomarkers in predicting treatment response, tracking cognitive change, and identifying molecular subtypes
• Emerging technologies, such as proteomics, and their use in developing predictive biomarker panels
• New frontiers in biomarker discovery, including alpha-synuclein seed aggregation assays and dopamine decarboxylase for detecting co-pathologies
This episode is essential for neurologists, clinical researchers, biomarker scientists, and healthcare professionals aiming to integrate biomarkers into routine dementia care and tailor treatments in the era of disease-modifying therapies.
This podcast was created using AI to provide a quick and insightful summary of an AD/PD™ 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.
The AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, took place on April 1-5, 2025, in Vienna Austria.
https://adpd.kenes.com/
In this episode of AD/PD™ Session Spotlight, we delve into Forum Discussion 1, "Varying Regulatory Philosophies and AD Approval Priorities – USA, EU, Asia, and Other Parts of the World," a dynamic exchange exploring how regional regulatory approaches impact the development, approval, and accessibility of Alzheimer’s disease therapies.
Co-moderated by Agneta Nordberg (Sweden) and David Holtzman (USA), this discussion brings together insights from international regulatory and clinical experts: Naohiro Egawa (Japan), Tamara Shiner (Israel), Henrik Zetterberg (Sweden), and Pavel Balabanov (The Netherlands).
Key highlights include:
• The complex landscape of disease-modifying drug approvals, exemplified by the case of kinumab
• Contrasts in regulatory frameworks between the EMA, FDA, and Japan’s PMDA
• The evolving role of biomarkers in diagnosis and treatment selection
• Ongoing challenges in balancing risk, clinical utility, and access across diverse healthcare systems
This episode is a must-listen for global stakeholders in Alzheimer’s research, regulation, and clinical care, looking to navigate the nuances of regional policy and foster cross-border collaboration in advancing neurodegenerative disease treatments.
This podcast was created using AI to provide a quick and insightful summary of an AD/PD™ 2025 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.
The AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, took place on April 1-5, 2025, in Vienna Austria.
https://adpd.kenes.com/
Welcome to AD/PD™ Session Spotlight, an official podcast series by AD/PD™. The podcast will discuss the latest cutting-edge science and real-world clinical impact in Alzheimer’s, Parkinson’s, and related neurodegenerative diseases, presented at the AD/PD™ 2025 Conference.
This AI-generated series is built for medical professionals and researchers who want to stay current with the latest breakthroughs without missing a step. Each episode offers concise, curated summaries of key sessions from the AD/PD™ 2025 Conference in Vienna. From novel therapies and biomarker discovery to translational research and trial data, we’ll spotlight the science that’s moving the field forward.
Whether you’re joining us in person or tuning in from your lab, clinic, or office, this podcast brings the heart of the Conference directly to you.
Powered by AI. Driven by science.
AD/PD™ 2025 took place April 1–5, 2025 in Vienna, Austria.
For more information visit https://adpd.kenes.com
Explore year-round learning with AD/PD™ Education on UNLOK: https://unlok-education.com/ad-pd/
